Prescription Required: Yes
Product Details:
| SLA1504(Methadone) | | |
| SKU | |
| CMI Product Code: | SLA1504 |
| Manufacturer: | AstraZeneca |
| Country of Origin: | Made in India |
ABSTRACT
Background:
Yasmin is used as an antineoplast 5-HT-dependent norepinephrine transporter agonist and -hypotensive agent in patients with hypogonadism, and in patients with diabetes mellitus. Yasmin has anti-proliferative, anti-apoptotic, and anti-hyperglycemic actions, and can be used in combination with other agents to improve insulin action, as an adjunct to diet and exercise for diabetes in diabetic patients.
Objective:
To evaluate the effect of YASMIN therapy in patients with hypogonadism.
Methods:
We prospectively evaluated the effect of the combination of YASMIN and metformin on the following laboratory parameters: (1) serum testosterone, (2) serum insulin, (3) blood glucose, (4) blood triglyceride, and (5) blood potassium.
Results:
The combination of the oral tablets (400mg), with the intravenous (IV) oral tablets (400mg) and the metformin hydrochloride (400mg) had a significant improvement in the laboratory parameters after 24 weeks (p<0.0001). In addition, the patients receiving YASMIN therapy had improved laboratory parameters in comparison with the control group.
Conclusion:
The combination of the oral tablets (400mg) with the IV oral tablets (400mg) and the metformin hydrochloride (400mg) had a significant improvement in the laboratory parameters after 24 weeks (p<0.0001).
| Yasmin Tablet | 0.5gm |
| SKU1504 | 400mg |
IMPORTANT:
Patients with hypogonadism or hypocalcemic coma, diabetes mellitus and diabetes or insulin resistant hyperinsulinemia should take this medicine with caution. There is limited evidence that these patients receive adequate doses of YASMIN for the prevention of the clinical symptoms of hyperglycemia. Therefore, it may also be necessary to increase the dose of the drug.
There is insufficient data to conclude that the combination of the oral tablets with the intravenous tablets or the metformin hydrochloride has a positive effect on the serum concentration of YASMIN, which could be considered as an indication for the drug combination. Therefore, patients taking the combination of the oral tablets with the intravenous tablets may need to continue treatment with YASMIN.
The combined oral tablets (400mg) with the IV oral tablets (400mg) and the metformin hydrochloride (400mg) had a significant improvement in the laboratory parameters after 24 weeks (p<0.0001). In addition, the patients receiving the combination of the oral tablets with the IV oral tablets or the metformin hydrochloride had improved laboratory parameters in comparison with the control group.
YASMIN is a female beauty treatment that combines Yasmin with Yasmin and Yasmin and contains the active ingredientsYasmin. It is a natural-looking form of Yasmin, and its active ingredients are female hormones (estradiol, triestradiol, and progesterone). Yasmin is available in various formulations, including tablet, capsule, and liquid suspensions. It is also available in tablets, liquid suspension, and gels. Yasmin is suitable for women who need a natural, natural-looking female product. Yasmin is usually prescribed to women who are pregnant, breastfeeding, and are experiencing preterm labor or who have a history of allergies to other ingredients. It is recommended to start Yasmin by taking Yasmin and a few other birth control pills. Yasmin is taken during the early part of the first trimester of pregnancy, at the beginning of the second trimester of pregnancy, or at the beginning of the third trimester of pregnancy. Yasmin may be prescribed as a birth control method during breastfeeding and after the first trimester of pregnancy, and it may be used during breastfeeding, along with other birth control pills, to prevent pregnancy.
Yasmin is available in different dosages, including 1.5 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 40 mg. Each dose is determined based on the individual woman’s response to the different strengths. The starting dose for women who are not pregnant or are planning to become pregnant is 1.5 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, and 20 mg. It is important to take the lowest dose that is effective in preventing pregnancy. This dosage may be started in women who are pregnant, breastfeeding, and may be taken during breastfeeding, during the first trimester of pregnancy, and during the first weeks of pregnancy, or after the first trimester of pregnancy.
It is important to take Yasmin at the same time each day as prescribed to prevent pregnancy. However, the recommended doses of Yasmin should not be missed. It is recommended to take the lowest dose that is effective in preventing pregnancy when it is taken correctly. The daily dose is taken at the same time each day as prescribed by the doctor and should not be missed. It is important to continue the Yasmin for the prescribed duration, but the daily dose should not be increased or decreased in order to ensure that the benefits of the Yasmin continue. The maximum recommended dose of Yasmin for women who are pregnant, breastfeeding, or are experiencing preterm labor or a history of allergies to other ingredients should not exceed 150 mg of Yasmin per day.
If you miss a dose, take the dose that is effective in preventing pregnancy when it is given as suggested by the doctor. The recommended dose of Yasmin is a 1-tablet, 7.5 mg tablet. The daily dose of Yasmin should not be increased or decreased in order to ensure that the benefits of the Yasmin continue. If you take the recommended dose of Yasmin, do not increase or decrease the dosage or have missed the dose. You should take the missed dose of Yasmin at the same time each day. If you are a woman who is planning to have a pregnancy, it is advisable to avoid taking the missed dose of Yasmin. It is important to take the recommended dose of Yasmin as advised by the doctor. Do not increase or decrease the dose of Yasmin.
Yasmin and other female products are associated with several side effects that may be serious and may require medical attention. Common side effects of Yasmin are nausea, vomiting, diarrhea, breast tenderness, headache, dizziness, dizziness, drowsiness, fatigue, and headache. Common side effects of Yasmin include breast tenderness, vaginal irritation, and headaches. More serious side effects of Yasmin may occur when the Yasmin and other female products are combined with other medications that interact with the female hormone progesterone. The risks and benefits of Yasmin in combination with other female products may be increased.
A new study, which is based in the U. S. and funded by a grant from Pfizer, suggests that men who have been prescribed Yasmin, an estrogen-progestogen combination, might experience the same levels of a potentially unpleasant side effect, according to results presented here at the annual meeting of the Society for Endocrine and Steroid Responses.
The results come from a study in the journal Addictive Behaviors, which has a long history of studies supporting these findings.
The study, led by researchers at the University of California, San Francisco, and from the University of Pennsylvania, found that men who took Yasmin were at a slightly higher risk of experiencing adverse side effects, including:
The results suggest that Yasmin may not cause these side effects and should be taken seriously. Yasmin is typically prescribed to men who are suffering from heavy or prolonged periods of heavy or heavy drinking.
In addition to the research, the U. study found that men taking Yasmin were less likely to develop severe complications such as acne or osteoporosis, in addition to other common causes of the disorder.
The study was funded by a grant from Pfizer, a research institution that has been around for more than 40 years and is part of the Center for Sexual Medicine at the University of California, San Francisco.
Dr. Joseph D’aughlin, who was lead investigator on the study, said the results “are an important first step in understanding the potential link between Yasmin and acne and osteoporosis.”
“We have to be realistic when it comes to using this medication to treat women of childbearing age,” he said. “It’s a little bit of a balancing act.”
D'aughlin, who led the study, was one of the authors of a paper presented in the journal Addictive Behaviors. The study, which was funded by a grant from Pfizer, was published online June 19. It was presented in part at the annual meeting of the Society for Endocrine and Steroid Responses. It is the most recent study to examine Yasmin use among US women. The study found that Yasmin is generally safe and effective in the treatment of female acne.
However, D'aughlin said, “There are many factors that influence how we think about the treatment of acne in women. These include the patient’s sexual history, their medical history, their age, their weight, their smoking status, their diet, their depression, their age at first intercourse, and more.”
He added that “we do not know exactly how much of this medication is safe, safe, and effective.”
“We don’t know exactly what’s in this medication, but we know that the amount of estrogen is associated with acne, and we know that there are certain drugs that are associated with acne that have not been studied,” he said.
“And we do know that when we’re looking at the effects of the drugs on the body, we don’t know exactly what’s in this medication.”
The research was supported by the National Institutes of Health, the Robert Wood Johnson Foundation, and the Sexual Medicine Program of the Medical Research Council.
The study was published online June 19 in the Journal of Sexual Medicine.
This press release contains forward-looking statements.
Joint StaffThis press release contains forward-looking statements, including any statements related to the potential risks and uncertainties that may arise from the study, the results, conclusions and analysis of the results, the regulatory and commercial environment, the use of these products by healthcare professionals and the analysis of data. These risks include the risks and uncertainties that arise from the study and that have been known to the public and/or to the authorities in the area, including to the U. Food and Drug Administration, the impact of the study and the timing of the results, including the availability of generic versions of these drugs and their generic equivalents.
PfizerPlease see the.
UCSF“We will not provide you with any of the information you may be entitled to under the terms of this press release, except as provided by our U. attorneys. You are not authorized to practice law in any state in which you have been licensed to practice law.
Introduction:This study aims to assess the efficacy of Yasmin in post-menopausal women with hot flashes (HT) and to determine whether the adverse effects are related to the hormonal environment, which might affect the patients' sexual function.
Methods:This was a single center, randomized, double-blind, cross-over, parallel-group, multicenter study in women with a hot flash for at least six months, taking a daily oral contraceptive, and who were using a selective estrogen receptor modulator (SERM).
Results:Of the total sample, 21 women participated in this study; 5 were on treatment and 2 on placebo. The mean age was 47.1 (SD = 7.9) years. The women with hot flashes were significantly more likely to have had HT than non-HT, but this was not significantly different from non-HT. The mean duration of HT was 4.5 (SD = 2.1) years. The most common sexual function parameters in women with HT were reduced desire to engage in sex (3.1, SD = 2.9), decreased sexual desire (3.4, SD = 3.6) and decreased arousal (2.9, SD = 4.1).
Conclusions:The present study suggests that the efficacy of Yasmin in post-menopausal women with HT and the mechanism of its action on the female sexual response is similar to that of the non-hormonal hormone, estradiol, and thus the potential adverse effects on the sexual function could be excluded.
Figure 1. The effectiveness of Yasmin in premenopausal women with hot flashes for 6 months. ATable of contentsshows the number of women in each group and mean age and the duration of the treatment. The women with HT were significantly more likely to have HT than non-HT, but this was not significantly different from non-HT. The most common sexual function parameters in women with HT were reduced desire to engage in sex (3.1, SD = 2.9) and decreased sexual desire (3.4, SD = 3.6) and were also significantly different from non-HT. The most common sexual function parameters in women with HT were reduced desire to engage in sex (3.1, SD = 2.9) and decreased sexual desire (3.4, SD = 3.6) and were significantly different from non-HT. The most common sexual function parameters in women with HT were reduced desire to engage in sex (2.9, SD = 4.1) and decreased sexual desire (2.9, SD = 4.1).Figure 2.
Table 1. The number of women in each group and mean age and the duration of the treatment. The most common sexual function parameters in women with HT were reduced desire to engage in sex (3.1, SD = 2.9) and decreased sexual desire (3.4, SD = 3.6).
Table 2. The mean duration of HT in women with hot flashes and the women with non-HT had the lowest mean duration of HT in all the groups (3.1, SD = 2.9).
Table 3.
Stade de France Pharmacy